The half-lives of warfarin and trimethoprim were significantly longer in mice acutely infected with Bacillus piliformis and in mice which had clinically recovered from previous experimental infection with the organism. The volume of distribution of trimethoprim but not of warfarin was significantly greater in infected mice than in controls. Body clearance of warfarin was significantly reduced in both disease states. For trimethoprim this parameter was only reduced in the acute state of the disease.
The importance of careful control of Tyzzer's disease in laboratory animals for use in pharmacological research is stressed.
References
1.
AggelerP. M., O'ReillyR. A., RollerF., DuckertF., & StreuliF. (1966). Pathogenesis and treatment of thromboembolic diseases.Stuttgart: Schaffauer.
2.
BlaschkeT. F. (1977). Protein binding and kinetics of drugs in liver diseases. Clinical Pharmacokinetics2, 32–44.
3.
BranchR. A., JamesJ., & ReadA. E. (1976). A study of factors influencing drug disposition in chronic liver disease, using the model drug (+)-propranolol. British Journal of Clinical Pharmacology3, 243–249.
FriesA. S. (1977a). Studies on Tyzzer's disease: application of immunofluorescence for detection of Bacillus piliformis and for demonstration and determination of antibodies to it in sera from mice and rabbits. Laboratory Animals11, 69–73.
7.
FriesA. S. (1977b). Studies on Tyzzer's disease: isolation and propagation of Bacillus piliformis. Laboratory Animals11, 75–78.
8.
FriesA. S. (1978). Demonstration of antibodies to Bacillus piliformis in SPF colonies and experimental transplacental infection by Bacillus piliformis in mice. Laboratory Animals12, 23–26.
9.
FriesA. S. (1979a). Studies on Tyzzer's disease: a long-term study on the humoral antibody response in mice, rats and rabbits. Laboratory Animals13, 37–41.
10.
FriesA. S. (1979b). Studies on Tyzzer's disease: transplacental transmission of Bacillus piliformis in rats. Laboratory Animals13, 43–46.
11.
FriesA. S., & SvendsenO. (1978). Studies on Tyzzer's disease in rats. Laboratory Animals12, 1–4.
12.
HeniN., LehnhardtG., & GlognerP. (1976). Eliminations-kinetik von phenprocoumon (MarcumarR) bei leber-zirrhose und nach vorbehandlung mit phenobarbital. International Journal of Clinical Pharmacology and Biopharmacy13, 253–261.
13.
KlotzU. (1976). Influence of liver disease on the elimination of drugs. European Journal of Drug Metabolism and Pharmacokinetics3, 129–140.
14.
LadefogedO. (1977). Pharmacokinetics of trimethoprim (TMP) in normal and febrile rabbits. Acta pharmacologica et toxicologica41, 507–514.
15.
LadefogedO. (1978). Endotoxin induced changes in the pharmacokinetics of warfarin in rabbits. Acta veterinaria scandinavica19, 479–486.
16.
PessayreD., AllemandH., & BenhamouJ. P. (1977). Effets des maladies du foie et des voies biliaires sur le métabolisme des médicaments. Nouvelle Presse médicale6, 3209–3219.
17.
RiederJ., & SchwartzD. E. (1975). Pharmakokinetik der wirkstofkombination trimethoprim + sulfamethoxazol bei leberkranken im vergleich zu gesunden. Arzneimittel-Forschung25, 656–666.
18.
RowlandM., BenetL. Z., & GrahamG. C. (1973) Clearance concepts in pharmacokinetics. Journal of Pharmacokinetics and Biopharmaceutics1, 123–136.
19.
SchwartzD. E., KoechinB. A., & WeinfeldR. E. (1969). Spectrofluorimetric method for the determination of trimethoprim in body fluids. Chemotherapy, Basel Supplement14, 22–29.
20.
WilkinsonG. R., & SchenkerS. (1975). Drug disposition and liver disease. Drug Metabolism Reviews4, 139–175.
21.
WilkinsonG. R., & SchenkerS. (1976). Effects of liver disease on drug disposition in man. Biochemical Pharmacology25, 2675–2681.
22.
WilliamsR. L., ScharyW. L., BlaschkeT. F., MeffinP. J., MelmonK. L., & RowlandM. (1976a). Influence of acute viral hepatitis on disposition and pharmacologic effect of warfarin. Clinical Pharmacology and Therapeutics20, 90–97.
23.
WilliamsR. L., BlaschkeT. F., MeffinP. J., MelmonK. L., & RowlandM. (1976b). Influence of viral hepatitis on the disposition of two compounds with high hepatic clearance: lidocain and indocyanine green. Clinical Pharmacology and Therapeutics20, 290–299.
